Age 0 3 0 3 B-age
≥ 4 5 4 5 O
18 6 8 6 8 B-lower_bound
years 9 14 9 14 I-lower_bound

Margin 0 6 15 21 B-treatment
negative 7 15 22 30 I-treatment
surgery 16 23 31 38 I-treatment
. 23 24 38 39 O
For 25 28 40 43 O
subjects 29 37 44 52 O
with 38 42 53 57 O
two 43 46 58 61 O
breasts 47 54 62 69 O
, 54 55 69 70 O
they 56 60 71 75 O
must 61 65 76 80 O
have 66 70 81 85 O
had 71 74 86 89 O
a 75 76 90 91 O
bilateral 77 86 92 101 O
mammogram 87 96 102 111 O
prior 97 102 112 117 O
to 103 105 118 120 O
surgery 106 113 121 128 O

Patient 0 7 129 136 O
has 8 11 137 140 O
a 12 13 141 142 O
serious 14 21 143 150 O
medical 22 29 151 158 O
or 30 32 159 161 O
physciatric 33 44 162 173 B-chronic_disease
illness 45 52 174 181 I-chronic_disease
which 53 58 182 187 O
prevents 59 67 188 196 O
informed 68 76 197 205 O
consent 77 84 206 213 O
or 85 87 214 216 O
adherence 88 97 217 226 O
with 98 102 227 231 O
treatment 103 112 232 241 B-treatment
Study 113 118 242 247 O
team 119 123 248 252 O
( 124 125 253 254 O
PI 125 127 254 256 O
, 127 128 256 257 O
Co 129 131 258 260 O
- 131 132 260 261 O
I 132 133 261 262 O
, 133 134 262 263 O
and 135 138 264 267 O
or 139 141 268 270 O
research 142 150 271 279 O
nurse 151 156 280 285 O
) 156 157 285 286 O
may 158 161 287 290 O
deny 162 166 291 295 O
enrollment 167 177 296 306 O
if 178 180 307 309 O
in 181 183 310 312 O
the 184 187 313 316 O
study 188 193 317 322 O
team 194 198 323 327 O
's 198 200 327 329 O
opinion 201 208 330 337 O
, 208 209 337 338 O
the 210 213 339 342 O
candidate 214 223 343 352 O
may 224 227 353 356 O
not 228 231 357 360 O
be 232 234 361 363 O
adherent 235 243 364 372 O
to 244 246 373 375 O
the 247 250 376 379 O
treatment 251 260 380 389 O
protocol 261 269 390 398 O
including 270 279 399 408 O
scheduled 280 289 409 418 O
follow 290 296 419 425 O
- 296 297 425 426 O
ups 297 300 426 429 O

Patient 0 7 430 437 O
has 8 11 438 441 O
other 12 17 442 447 O
prior 18 23 448 453 B-cancer
malignancy 24 34 454 464 I-cancer
except 35 41 465 471 O
for 42 45 472 475 O
adequately 46 56 476 486 O
treated 57 64 487 494 O
basal 65 70 495 500 B-cancer
cell 71 75 501 505 I-cancer
or 76 78 506 508 O
squamous 79 87 509 517 B-cancer
cell 88 92 518 522 I-cancer
skin 93 97 523 527 I-cancer
cancer 98 104 528 534 I-cancer
, 104 105 534 535 O
in 106 108 536 538 B-cancer
sity 109 113 539 543 I-cancer
cervical 114 122 544 552 I-cancer
cancer 123 129 553 559 I-cancer
, 129 130 559 560 O
or 131 133 561 563 O
any 134 137 564 567 O
other 138 143 568 573 O
cancer 144 150 574 580 O
from 151 155 581 585 O
which 156 161 586 591 O
the 162 165 592 595 O
patient 166 173 596 603 O
has 174 177 604 607 O
been 178 182 608 612 O
disease 183 190 613 620 O
- 190 191 620 621 O
free 191 195 621 625 O
for 196 199 626 629 O
less 200 204 630 634 O
than 205 209 635 639 O
5 210 211 640 641 B-upper_bound
years 212 217 642 647 I-upper_bound

Patient 0 7 648 655 O
is 8 10 656 658 O
pregnant 11 19 659 667 B-pregnancy

Patient 0 7 668 675 O
must 8 12 676 680 O
have 13 17 681 685 O
a 18 19 686 687 O
Medical 20 27 688 695 O
Oncology 28 36 696 704 O
consult 37 44 705 712 O
with 45 49 713 717 O
the 50 53 718 721 O
recommendation 54 68 722 736 O
of 69 71 737 739 O
chemotherapy 72 84 740 752 B-treatment

Patient 0 7 753 760 O
must 8 12 761 765 O
have 13 17 766 770 O
histologically 18 32 771 785 O
confirmed 33 42 786 795 O
( 43 44 796 797 O
by 44 46 797 799 O
routine 47 54 800 807 O
H&E 55 58 808 811 O
staining 59 67 812 820 O
) 67 68 820 821 O
invasive 69 77 822 830 O
adenocarcinoma 78 92 831 845 B-cancer
of 93 95 846 848 O
the 96 99 849 852 O
breast 100 106 853 859 O

Patients 0 8 860 868 O
who 9 12 869 872 O
have 13 17 873 877 O
received 18 26 878 886 O
neoadjuvant 27 38 887 898 B-treatment
chemotherapy 39 51 899 911 I-treatment
or 52 54 912 914 O
neoadjuvant 55 66 915 926 B-treatment
hormonal 67 75 927 935 I-treatment
therapy 76 83 936 943 I-treatment
for 84 87 944 947 O
the 88 91 948 951 O
current 92 99 952 959 O
cancer 100 106 960 966 B-cancer

Patients 0 8 967 975 O
with 9 13 976 980 O
squamous 14 22 981 989 B-cancer
or 23 25 990 992 O
sarcomas 26 34 993 1001 B-cancer
of 35 37 1002 1004 I-cancer
the 38 41 1005 1008 I-cancer
breast 42 48 1009 1015 I-cancer
. 48 49 1015 1016 O
Patients 50 58 1017 1025 O
who 59 62 1026 1029 O
have 63 67 1030 1034 O
active 68 74 1035 1041 O
local 75 80 1042 1047 O
- 80 81 1047 1048 O
regional 81 89 1048 1056 O
disease 90 97 1057 1064 O
prior 98 103 1065 1070 O
to 104 106 1071 1073 O
registration 107 119 1074 1086 O

Primary 0 7 1087 1094 B-clinical_variable
tumor 8 13 1095 1100 I-clinical_variable
≤ 14 15 1101 1102 O
4 16 17 1103 1104 B-upper_bound
cm 17 19 1104 1106 I-upper_bound
and 20 23 1107 1110 O
0 24 25 1111 1112 B-lower_bound
- 25 26 1112 1113 O
3 26 27 1113 1114 B-upper_bound
positive 28 36 1115 1123 B-clinical_variable
axillary 37 45 1124 1132 I-clinical_variable
lymph 46 51 1133 1138 O
nodes 52 57 1139 1144 O
( 58 59 1145 1146 O
T1 59 61 1146 1148 O
- 61 62 1148 1149 O
2 62 63 1149 1150 O
, 63 64 1150 1151 O
N0 65 67 1152 1154 O
- 67 68 1154 1155 O
1 68 69 1155 1156 O
, 69 70 1156 1157 O
M0 71 73 1158 1160 O
) 73 74 1160 1161 O

Recommended 0 11 1162 1173 O
regimens 12 20 1174 1182 O
are 21 24 1183 1186 O
as 25 27 1187 1189 O
follows 28 35 1190 1197 O
: 35 36 1197 1198 O
Cyclophosphamide 37 53 1199 1215 B-treatment
and 54 57 1216 1219 I-treatment
Doxorubicin 58 69 1220 1231 I-treatment
( 70 71 1232 1233 I-treatment
AC 71 73 1233 1235 I-treatment
) 73 74 1235 1236 I-treatment
; 74 75 1236 1237 O
Taxotere 76 84 1238 1246 B-treatment
, 84 85 1246 1247 O
Doxorubicin 86 97 1248 1259 B-treatment
and 98 101 1260 1263 I-treatment
Cyclophosphamide 102 118 1264 1280 I-treatment
( 119 120 1281 1282 I-treatment
TAC 120 123 1282 1285 I-treatment
) 123 124 1285 1286 I-treatment
; 124 125 1286 1287 O
Taxotere 126 134 1288 1296 B-treatment
and 135 138 1297 1300 I-treatment
Cyclophosphamide 139 155 1301 1317 I-treatment
( 156 157 1318 1319 I-treatment
TC 157 159 1319 1321 I-treatment
) 159 160 1321 1322 I-treatment
; 160 161 1322 1323 O
or 162 164 1324 1326 O
Taxotere 165 173 1327 1335 O
, 173 174 1335 1336 O
Carboplatin 175 186 1337 1348 B-treatment
and 187 190 1349 1352 I-treatment
Trastuzamab 191 202 1353 1364 I-treatment
( 203 204 1365 1366 I-treatment
TCH 204 207 1366 1369 I-treatment
) 207 208 1369 1370 I-treatment
prior 209 214 1371 1376 I-treatment
to 215 217 1377 1379 O
registration 218 230 1380 1392 O
. 230 231 1392 1393 O
The 232 235 1394 1397 O
use 236 239 1398 1401 O
of 240 242 1402 1404 O
additional 243 253 1405 1415 O
chemotherapy 254 266 1416 1428 B-treatment
, 266 267 1428 1429 O
hormonal 268 276 1430 1438 B-treatment
therapy 277 284 1439 1446 I-treatment
or 285 287 1447 1449 O
Trastuzumab 288 299 1450 1461 B-treatment
after 300 305 1462 1467 O
the 306 309 1468 1471 O
initial 310 317 1472 1479 O
regimen 318 325 1480 1487 O
is 326 328 1488 1490 O
at 329 331 1491 1493 O
the 332 335 1494 1497 O
discretion 336 346 1498 1508 O
of 347 349 1509 1511 O
the 350 353 1512 1515 O
Medical 354 361 1516 1523 O
Oncologist 362 372 1524 1534 O
. 372 373 1534 1535 O
Other 374 379 1536 1541 O
primary 380 387 1542 1549 O
regimens 388 396 1550 1558 O
are 397 400 1559 1562 O
possible 401 409 1563 1571 O
but 410 413 1572 1575 O
the 414 417 1576 1579 O
PI 418 420 1580 1582 O
must 421 425 1583 1587 O
be 426 428 1588 1590 O
notified 429 437 1591 1599 O
prior 438 443 1600 1605 O
to 444 446 1606 1608 O
enrollment 447 457 1609 1619 O
. 457 458 1619 1620 O
Partial 459 466 1621 1628 B-treatment
breast 467 473 1629 1635 I-treatment
irradiation 474 485 1636 1647 I-treatment
must 486 490 1648 1652 O
be 491 493 1653 1655 O
scheduled 494 503 1656 1665 O
to 504 506 1666 1668 O
begin 507 512 1669 1674 O
less 513 517 1675 1679 O
than 518 522 1680 1684 O
71 523 525 1685 1687 B-lower_bound
days 526 530 1688 1692 I-lower_bound
from 531 535 1693 1697 O
the 536 539 1698 1701 O
last 540 544 1702 1706 O
breast 545 551 1707 1713 B-treatment
surgical 552 560 1714 1722 I-treatment
procedure 561 570 1723 1732 O
. 570 571 1732 1733 O
ECOG 572 576 1734 1738 B-clinical_variable
performance 577 588 1739 1750 I-clinical_variable
status 589 595 1751 1757 I-clinical_variable
≤ 596 597 1758 1759 O
1 598 599 1760 1761 O
. 599 600 1761 1762 O
Women 601 606 1763 1768 B-gender
of 607 609 1769 1771 O
child 610 615 1772 1777 O
- 615 616 1777 1778 O
bearing 616 623 1778 1785 O
potential 624 633 1786 1795 O
must 634 638 1796 1800 O
have 639 643 1801 1805 O
a 644 645 1806 1807 O
negative 646 654 1808 1816 B-pregnancy
( 655 656 1817 1818 I-pregnancy
urine 656 661 1818 1823 I-pregnancy
or 662 664 1824 1826 I-pregnancy
blood 665 670 1827 1832 I-pregnancy
) 670 671 1832 1833 I-pregnancy
pregnancy 672 681 1834 1843 I-pregnancy
test 682 686 1844 1848 O
within 687 693 1849 1855 O
6 694 695 1856 1857 B-upper_bound
weeks 696 701 1858 1863 I-upper_bound
prior 702 707 1864 1869 I-upper_bound
to 708 710 1870 1872 O
start 711 716 1873 1878 O
of 717 719 1879 1881 O
protocol 720 728 1882 1890 B-treatment
therapy 729 736 1891 1898 I-treatment
. 736 737 1898 1899 O
Women 738 743 1900 1905 O
of 744 746 1906 1908 O
childbearing 747 759 1909 1921 O
potential 760 769 1922 1931 O
must 770 774 1932 1936 O
also 775 779 1937 1941 O
use 780 783 1942 1945 B-contraception_consent
effective 784 793 1946 1955 I-contraception_consent
non 794 797 1956 1959 I-contraception_consent
- 797 798 1959 1960 I-contraception_consent
hormonal 798 806 1960 1968 I-contraception_consent
contraception 807 820 1969 1982 I-contraception_consent
while 821 826 1983 1988 O
undergoing 827 837 1989 1999 O
radiation 838 847 2000 2009 B-treatment
therapy 848 855 2010 2017 I-treatment
. 855 856 2017 2018 O
Ability 857 864 2019 2026 O
to 865 867 2027 2029 O
understand 868 878 2030 2040 O
and 879 882 2041 2044 O
the 883 886 2045 2048 O
willingness 887 898 2049 2060 O
to 899 901 2061 2063 O
sign 902 906 2064 2068 O
a 907 908 2069 2070 O
written 909 916 2071 2078 O
informed 917 925 2079 2087 O
consent 926 933 2088 2095 O
document 934 942 2096 2104 O

